We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,073

EMEA Healthcare Industry Group Newsletter - December 2015
  • Baker & McKenzie
  • Belgium, European Union, Germany, Italy, Netherlands, Saudi Arabia, Spain, United Arab Emirates, United Kingdom
  • January 25 2016

The Eurasian Economic Union (EAEU) is introducing major new changes in the marketing of pharmaceuticals across its members - which include Russia

European pharmaceuticals & healthcare newsletter - April 2015
  • Baker & McKenzie
  • European Union, France, Hungary, Italy, United Kingdom
  • April 30 2015

This is a rare example of a major product liability dispute being referred to the European Court of Justice ("ECJ"). The two issues to be decided by

New active substances and global marketing authorisations
  • Taylor Wessing
  • European Union
  • April 20 2015

Data and marketing exclusivity (otherwise known as regulatory data protection) prevents the use of pre-clinical and clinical data produced for the

European Commission clarifies position on post-authorisation efficacy studies
  • Hogan Lovells
  • European Union
  • May 8 2014

On 10 April 2014, the European Commission ("Commission") adopted Commission Delegated Regulation (EU) No 3572014 as regards situations in which

French legal and regulatory update - April 2014
  • Hogan Lovells
  • European Union, France
  • May 1 2014

Draft law granting amnesty for acts committed in the course of social movements and trade unions' protesting activities Filed on November 28, 2012

Network interference - a legal guide to the commercial risks and rewards of the social media phenomenon
  • Reed Smith LLP
  • United Kingdom, USA, European Union, Global
  • April 22 2014

Social media is a revolution in the way in which corporations communicate with consumers. This White Paper will help you to maximise the huge

More clarity for complex biosimilars: Europe approved the first follow-on monoclonal antibodies Canada follows suit
  • Bereskin & Parr LLP
  • Canada, European Union
  • March 7 2014

Last year, the European Medicines Agency (EMA) granted marketing authorizations to two biosimilar versions of Johnson & Johnson's rheumatoid

Medicinal products : information and advertising
  • CMS DeBacker
  • European Union
  • March 4 2014

Five years after the European Court of Justice (the "ECJ") rendered its judgment in the Damgaard case (Case C-42107, judgment of 2 April 2009

Antitrust and competition the EU weekly briefing (21 January 2014)
  • Winston & Strawn LLP
  • European Union, United Kingdom
  • January 21 2014

On 13 January 2014, the European Commission (Commission) announced formal proceedings to investigate restrictions concerning the provision of

Prescription medicines: how to differentiate information from advertising in the EU
  • Stibbe
  • European Union
  • March 5 2012

The question of how to distinguish between advertising and providing information on prescription medicines has returned to the spotlight, following the European Commission's publication of its revised proposals on information to patients and pharmacovigilance in February